Problems in the reproducibility of classification of small lung adenocarcinoma: an international interobserver study
- PMID: 31107973
- DOI: 10.1111/his.13922
Problems in the reproducibility of classification of small lung adenocarcinoma: an international interobserver study
Abstract
Aims: The 2015 WHO classification for lung adenocarcinoma (ACA) provides criteria for adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (INV), but differentiating these entities can be difficult. As our understanding of prognostic significance increases, inconsistent classification is problematic. This study assesses agreement within an international panel of lung pathologists and identifies factors contributing to inconsistent classification.
Methods and results: Sixty slides of small lung ACAs were reviewed digitally by six lung pathologists in three rounds, with consensus conferences and examination of elastic stains in round 3. The panel independently reviewed each case to assess final diagnosis, invasive component size and predominant pattern. The kappa value for AIS and MIA versus INV decreased from 0.44 (round 1) to 0.30 and 0.34 (rounds 2 and 3). Interobserver agreement for invasion (AIS versus other) decreased from 0.34 (round 1) to 0.29 and 0.29 (rounds 2 and 3). The range of the measured invasive component in a single case was up to 19.2 mm among observers. Agreement was excellent in tumours with high-grade cytology and fair with low-grade cytology.
Conclusions: Interobserver agreement in small lung ACAs was fair to moderate, and improved minimally with elastic stains. Poor agreement is primarily attributable to subjectivity in pattern recognition, but high-grade cytology increases agreement. More reliable methods to differentiate histological patterns may be necessary, including refinement of the definitions as well as recognition of other features (such as high-grade cytology) as a formal part of routine assessment.
Keywords: histological pattern; interobserver agreement; lung adenocarcinoma; minimally invasive adenocarcinoma.
© 2019 John Wiley & Sons Ltd.
References
-
- Jemal A, Ward EM, Johnson CJ et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J. Natl Cancer Inst. 2017; 109; djx030.
-
- Chen VW, Ruiz BA, Hsieh M et al. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer. 2014; 120; 3781-3792.
-
- Ferrara R, Mezquita L, Besse B. Progress in the management of advanced thoracic malignancies in 2017. J. Thorac. Oncol. 2018; 13; 301-322.
-
- Aberle DR, Adams AM, Berg CD et al. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J Med. 2011; 365; 395-409.
-
- Fintelmann FJ, Bernheim A, Digumarthy SR et al. The 10 pillars of lung cancer screening: rationale and logistics of a lung cancer screening program. Radiographics 2015; 35; 1893-1908.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials